SCHEMBL245476

SCHEMBL245476

Fc1ccc(NC2CC2)cc1F

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KCNQ3 O43525 1/20 0.48
KCNQ2 O43526 1/20 0.48
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
RAPGEF4 Q8WZA2 1/20 0.46
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.40
KDM1A O60341 1/20 0.40
KDM4E B2RXH2 1/20 0.40
BACE1 P56817 2/20 0.40
BACE2 Q9Y5Z0 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17502528 0.98 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL14506690 0.90 KMT2A (0.46) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL25039539 0.90 KDM1A (0.53) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL1704674 0.86 KDM1A (0.53) NPC1RAB9ASMN1; SMN2PTGS1PTGS2
SCHEMBL31453688 0.84 KMT2A (0.59) KMT2ARAPGEF4MEN1ALDH1A1
SCHEMBL9008342 0.84 KMT2A (0.59) KMT2ARAPGEF4MEN1ALDH1A1
SCHEMBL9442760 0.84 KCNQ3 (0.40) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL29218593 0.79 KCNQ3 (0.47) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL17048125 0.79 KMT2A (0.47) RAB9APTGS1PTGS2KMT2APOLB
SCHEMBL6559446 0.79 KDM1A (0.47) NPC1RAB9ASMN1; SMN2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113582906-A Difluorophenyl ring propylamine compound and preparation method and application thereof 郑州大学 2021-11-02 CN claimed
CN-109553622-A A kind of preparation method of ticagrelor impurity 扬子江药业集团有限公司 2019-04-02 CN claimed
WO-2017072790-A1 AN IMPROVED PROCESS FOR SYNTHESIS OF TICAGRELOR AVRA LABORATORIES PVT. LTD. (IN) 2017-05-04 WO claimed
EP-2588441-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR Actavis Group Ptc Ehf (IS) 2013-05-08 EP claimed
WO-2012001531-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2012-01-05 WO claimed
EP-0990639-B1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL IND CO (JP) 2004-02-25 EP claimed
US-6162944-A Process for production of N-cyclopropylanilines and intermediates therefor IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2000-12-19 US claimed
EP-0990639-A1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-04-05 EP claimed
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 US disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 EP disclosed
EP-3955929-B1 NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING UNIV LIEGE (BE) 2024-05-15 EP disclosed
CN-115368245-B Preparation method of hydrochloride crystal form of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine 上海医药工业研究院 2024-03-22 CN disclosed
CN-115368245-B Preparation method of hydrochloride crystal form of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine 上海医药工业研究院 2024-03-22 CN disclosed
CN-115368245-B Preparation method of hydrochloride crystal form of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine 上海医药工业研究院 2024-03-22 CN disclosed
EP-0990639-A4 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL IND CO (JP) 2002-08-14 EP disclosed
US-6162944-A Process for production of N-cyclopropylanilines and intermediates therefor IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2000-12-19 US disclosed
US-6162944-A Process for production of N-cyclopropylanilines and intermediates therefor IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2000-12-19 US disclosed
EP-0990639-A1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-04-05 EP disclosed
EP-0990639-A1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-04-05 EP disclosed
WO-1999050226-A1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 NPC1 297/4885RAB9A 1828/4885SMN1; SMN2 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.